OCUL - Ocular Therapeutix

-

$undefined

N/A

(N/A)

Ocular Therapeutix NasdaqGM:OCUL Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Location: 15 Crosby Drive, Bedford, MA, 01730, United States | Website: https://www.ocutx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.023B

Cash

349.7M

Avg Qtr Burn

-36.37M

Short % of Float

11.29%

Insider Ownership

3.49%

Institutional Own.

87.00%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DEXTENZA® (dexamethasone ophthalmic insert) Details
Inflammation and pain following ophthalmic surgery

Approved

Quarterly sales

DEXTENZA® (dexamethasone ophthalmic insert) Details
Eye disease , Allergic conjunctivitis

Approved

Quarterly sales

ReSure® Sealant Details
Intraoperative management of clear corneal incision

Approved

Quarterly sales

Phase 3

Data readout

Phase 2

Data readout

Phase 2

Data readout

PAXTRAVA™ (OTX-TIC) (travoprost implant) Details
Ocular hypertension, Primary open angle glaucoma

Phase 2

Update

Phase 1

Update